Keigo Ozono
Impact in
- Gastroenterology top 5%
- Gastrointestinal Tumor Research and Treatment
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Oncology 8
- Pancreatic and Hepatic Oncology Research 3
- Peptidase Inhibition and Analysis 3
- Vascular Tumors and Angiosarcomas 1
- Co-authors
- Kinjiro SumiyoshiKazuhiro KoikawaMasao TanakaKohei HoriokaShin AkagawaKenji FujiwaraMasayuki SadaNorihiro Sato
- Journals
- Anticancer Research (2 papers)Oncology Reports (1 paper)Pathobiology (1 paper)Histopathology (1 paper)Laboratory Investigation (1 paper)
- Partner nations
- JapanUnited States
In The Last Decade
Keigo Ozono
13 papers receiving 933 citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Gastroenterology 118
- Hepatology 161
- Oncology 309
- Surgery 484
- Pulmonary and Respiratory Medicine 283
Countries citing papers authored by Keigo Ozono
This map shows the geographic impact of Keigo Ozono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keigo Ozono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keigo Ozono more than expected).
Fields of papers citing papers by Keigo Ozono
This network shows the impact of papers produced by Keigo Ozono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keigo Ozono. The network helps show where Keigo Ozono may publish in the future.
Co-authors
The 25 scholars most cited alongside Keigo Ozono, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 1 | |
| 4 | 2024 | 0 | |
| 5 | 2023 | 1 | |
| 6 | 2022 | 2 | |
| 7 | 2022 | 8 | |
| 8 | 2018 | 5 | |
| 9 | 2018 | 9 | |
| 10 | 2018 | 24 | |
| 11 | 2017 | 6 | |
| 12 | 2017 | 6 | |
| 13 | 2017 | 24 | |
| 14 | 2017 | 14 | |
| 15 | 2016 | 3 | |
| 16 | 2011 | 0 | |
| 17 | Hepatogastroenterology Hit paper breakdown → | 2011 | 841 |
| 18 | 2008 | 1 |
About Keigo Ozono
Keigo Ozono is a scholar working on Microbiology, Oncology, Pathology and Forensic Medicine, Cancer Research and Neurology, having authored 18 papers that have together received 945 indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Cancer Mechanisms and Therapy (4 papers), Pancreatic and Hepatic Oncology Research (3 papers), Peptidase Inhibition and Analysis (3 papers), Myasthenia Gravis and Thymoma (2 papers), Cancer Genomics and Diagnostics (2 papers), Vascular Tumors and Angiosarcomas (1 paper) and Neuroendocrine Tumor Research Advances (1 paper). The work is most often cited by research in Gastroenterology (118 citations), Hepatology (161 citations), Oncology (309 citations), Surgery (484 citations) and Pulmonary and Respiratory Medicine (283 citations). Keigo Ozono has collaborated with scholars based in Japan and United States. Frequent co-authors include Kinjiro Sumiyoshi, Kazuhiro Koikawa, Masao Tanaka, Kohei Horioka, Shin Akagawa, Kenji Fujiwara, Masayuki Sada, Norihiro Sato, Tatsuya Hirano and Yoshinao Oda. Their work appears in journals such as Anticancer Research, Oncology Reports, Pathobiology, Histopathology and Laboratory Investigation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.